DexCom Inc at Stephens Investor Conference Transcript
Well, good morning, everyone. We'll keep it moving along here. Again, I'm Chris Cooley, the senior medical device analyst here at Stephens. We're honored to have the management team from DexCom with us here today to continue on our medical device track. Long-time friend, Steve Pacelli, here to my right, Executive Vice President of Strategy and Corporate Development. And we also have Sean Christensen as well, the Senior Investor Relations Manager for DexCom. So gentlemen, welcome. I appreciate you joining us here this morning.
Questions & Answers
We'll just jump right into the Q&A format. And I guess, for me to start, wow, third quarter, 49% annual growth, highest we've seen since early '16. And you did this despite having a number of headwinds that all of us, at least on the sell side, were modeling when we think about Medicare, international markets and the lost PDM sales.
So I guess, a couple of parts to the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |